Zydus Lifesciences Limited (ZYDUSLIFE.BO)
INR 984.0
(0.5%)
INR 984.0
(0.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 56.22 Billion INR | 63.18% |
| 2023 | 34.42 Billion INR | 14.87% |
| 2022 | 36.71 Billion INR | -1.97% |
| 2021 | 32.32 Billion INR | 25.68% |
| 2020 | 25.24 Billion INR | -8.9% |
| 2019 | 31.76 Billion INR | 4.35% |
| 2018 | 29.8 Billion INR | 47.0% |
| 2017 | 20.51 Billion INR | -17.0% |
| 2016 | 24.43 Billion INR | 33.07% |
| 2015 | 18 Billion INR | 40.74% |
| 2014 | 12.33 Billion INR | 14.35% |
| 2013 | 11.55 Billion INR | 5.41% |
| 2012 | 11.22 Billion INR | 2.25% |
| 2011 | 10.39 Billion INR | 25.35% |
| 2010 | 8.29 Billion INR | 32.4% |
| 2009 | 6.26 Billion INR | 33.66% |
| 2008 | 4.66 Billion INR | 23.78% |
| 2007 | 3.78 Billion INR | 29.93% |
| 2006 | 2.72 Billion INR | 18.46% |
| 2005 | 2.33 Billion INR | -4.02% |
| 2004 | 2.56 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 17.86 Billion INR | 56.73% |
| 2024 Q2 | 12 Billion INR | -21.41% |
| 2024 FY | - INR | 43.94% |
| 2024 Q3 | 11.4 Billion INR | -5.0% |
| 2024 Q1 | 15.41 Billion INR | 120.65% |
| 2023 Q2 | 8.59 Billion INR | -4.36% |
| 2023 FY | - INR | 14.87% |
| 2023 Q4 | 11.84 Billion INR | 19.15% |
| 2023 Q3 | 9.94 Billion INR | 15.68% |
| 2023 Q1 | 8.98 Billion INR | 26.06% |
| 2022 Q1 | 10.03 Billion INR | 19.99% |
| 2022 FY | - INR | -1.97% |
| 2022 Q4 | 7.13 Billion INR | -12.21% |
| 2022 Q3 | 8.12 Billion INR | -14.75% |
| 2022 Q2 | 9.52 Billion INR | -5.05% |
| 2021 Q2 | 8.41 Billion INR | 3.48% |
| 2021 FY | - INR | 25.68% |
| 2021 Q1 | 8.13 Billion INR | 6.68% |
| 2021 Q4 | 8.36 Billion INR | 5.37% |
| 2021 Q3 | 7.93 Billion INR | -5.66% |
| 2020 Q2 | 6.62 Billion INR | -2.76% |
| 2020 Q1 | 6.81 Billion INR | -4.07% |
| 2020 FY | - INR | -8.9% |
| 2020 Q4 | 7.62 Billion INR | 6.16% |
| 2020 Q3 | 7.17 Billion INR | 8.36% |
| 2019 Q2 | 7.18 Billion INR | -3.77% |
| 2019 Q4 | 7.1 Billion INR | -18.45% |
| 2019 Q1 | 7.46 Billion INR | -16.99% |
| 2019 Q3 | 8.7 Billion INR | 21.26% |
| 2019 FY | - INR | 4.35% |
| 2018 Q1 | 2.97 Billion INR | -44.62% |
| 2018 Q3 | 8.84 Billion INR | 0.53% |
| 2018 Q4 | 8.99 Billion INR | 1.67% |
| 2018 FY | - INR | 47.0% |
| 2018 Q2 | 8.79 Billion INR | 195.47% |
| 2017 Q1 | 5.39 Billion INR | -8.53% |
| 2017 FY | - INR | -17.0% |
| 2017 Q4 | 5.37 Billion INR | 27.73% |
| 2017 Q3 | 4.2 Billion INR | -21.39% |
| 2017 Q2 | 5.35 Billion INR | -0.7% |
| 2016 Q2 | 6.3 Billion INR | 4.8% |
| 2016 FY | - INR | 33.07% |
| 2016 Q3 | 6.24 Billion INR | -1.05% |
| 2016 Q1 | 6.01 Billion INR | 14.94% |
| 2016 Q4 | 5.89 Billion INR | -5.54% |
| 2015 Q2 | 4.35 Billion INR | 12.7% |
| 2015 Q3 | 4.72 Billion INR | 8.52% |
| 2015 Q4 | 5.23 Billion INR | 10.76% |
| 2015 Q1 | 3.86 Billion INR | -3.8% |
| 2015 FY | - INR | 40.74% |
| 2014 Q3 | 3.08 Billion INR | 12.93% |
| 2014 FY | - INR | 14.35% |
| 2014 Q4 | 4.01 Billion INR | 30.43% |
| 2014 Q2 | 2.72 Billion INR | -8.56% |
| 2014 Q1 | 2.98 Billion INR | 22.2% |
| 2013 Q1 | 3.66 Billion INR | 583.94% |
| 2013 Q2 | 2.37 Billion INR | -35.4% |
| 2013 Q3 | 2.63 Billion INR | 11.22% |
| 2013 FY | - INR | 5.41% |
| 2013 Q4 | 2.44 Billion INR | -7.39% |
| 2012 Q2 | 6.67 Billion INR | 0.0% |
| 2012 Q3 | 2.79 Billion INR | -58.08% |
| 2012 Q4 | -758.2 Million INR | -127.1% |
| 2012 FY | - INR | 2.25% |
| 2011 FY | - INR | 25.35% |
| 2010 FY | - INR | 32.4% |
| 2009 FY | - INR | 33.66% |
| 2008 FY | - INR | 23.78% |
| 2007 FY | - INR | 29.93% |
| 2006 FY | - INR | 18.46% |
| 2005 FY | - INR | -4.02% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | -347.435% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -8137.197% |
| Sigachi Industries Limited | 883.39 Million INR | -6264.289% |
| Bal Pharma Limited | 345.59 Million INR | -16168.316% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -719.367% |
| Medico Remedies Limited | 150.37 Million INR | -37287.118% |
| Lasa Supergenerics Limited | -65.08 Million INR | 86489.06% |
| Venus Remedies Limited | 711.8 Million INR | -7798.556% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 1606.78% |
| Alpa Laboratories Limited | 86.12 Million INR | -65178.02% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -3495.24% |
| Shilpa Medicare Limited | 2.58 Billion INR | -2072.425% |
| Aarti Drugs Limited | 3.24 Billion INR | -1630.637% |
| Lupin Limited | 36.96 Billion INR | -52.077% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 9.008% |
| Windlas Biotech Limited | 781.72 Million INR | -7092.089% |
| Suven Life Sciences Limited | -992.78 Million INR | 5763.087% |
| Eris Lifesciences Limited | 6.98 Billion INR | -704.729% |
| Valiant Laboratories Limited | 12.73 Million INR | -441237.625% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -502.283% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 2092.346% |
| Ipca Laboratories Limited | 13.29 Billion INR | -322.738% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -3701.275% |
| Achyut Healthcare Limited | 524 Thousand INR | -10729289.313% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 59.366% |
| Bajaj HealthCare Limited | 444.51 Million INR | -12547.914% |
| RPG Life Sciences Limited | 1.28 Billion INR | -4287.202% |
| Mankind Pharma Limited | 28.09 Billion INR | -100.116% |
| Laurus Labs Limited | 8 Billion INR | -602.248% |
| Piramal Pharma Limited | 13.05 Billion INR | -330.642% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -12966.497% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | -60.59% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -484.629% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -395.623% |
| Unichem Laboratories Limited | 742.35 Million INR | -7473.455% |
| Sequent Scientific Limited | 549.8 Million INR | -10125.9% |
| Novartis India Limited | 1.26 Billion INR | -4329.371% |
| Wanbury Limited | 985.49 Million INR | -5604.979% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -1102.049% |
| Wockhardt Limited | 1.08 Billion INR | -5105.741% |
| Themis Medicare Limited | 562.6 Million INR | -9893.121% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -17281.438% |
| Jubilant Pharmova Limited | 8 Billion INR | -602.248% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -719.219% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 36.31% |
| Divi's Laboratories Limited | 25.43 Billion INR | -121.085% |
| NATCO Pharma Limited | 18.79 Billion INR | -199.133% |
| Gufic Biosciences Limited | 1.48 Billion INR | -3697.537% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -2056.909% |
| Ind-Swift Limited | 1.06 Billion INR | -5178.734% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -1765.114% |
| FDC Limited | 4.4 Billion INR | -1177.283% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 68060.883% |
| Granules India Limited | 8.6 Billion INR | -553.454% |
| Medicamen Biotech Limited | 245.66 Million INR | -22786.103% |
| Alkem Laboratories Limited | 24.19 Billion INR | -132.369% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -2285.523% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -430324.131% |
| Brooks Laboratories Limited | 41.72 Million INR | -134634.471% |
| Megasoft Limited | 284.73 Million INR | -19645.655% |
| ZIM Laboratories Limited | 462.09 Million INR | -12066.71% |
| Strides Pharma Science Limited | 3.76 Billion INR | -1393.407% |
| Neuland Laboratories Limited | 4.74 Billion INR | -1084.074% |
| Morepen Laboratories Limited | 1.72 Billion INR | -3157.445% |
| Hikal Limited | 2.69 Billion INR | -1988.306% |
| Indoco Remedies Limited | 2.64 Billion INR | -2023.946% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -1338.117% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -19460.581% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -32036.774% |
| Hester Biosciences Limited | 539.47 Million INR | -10321.71% |